Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.43 |
| ▸ | HMGCR | P04035 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205602 | 0.89 | PTPN7 (0.30) | PTPN7HMGCR | |
| SCHEMBL26206496 | 0.88 | PTPN7 (0.45) | PTPN7HMGCRRECQLTDP1KDM4E | |
| SCHEMBL10481607 | 0.77 | HMGCR (0.53) | PTPN7HMGCRRECQLTDP1 | |
| SCHEMBL22527013 | 0.77 | PTPN7 (0.33) | PTPN7HMGCRBLMKMT2A | |
| SCHEMBL22540052 | 0.75 | PTPN7 (0.70) | PTPN7HMGCRRECQLTDP1KDM4E | |
| SCHEMBL5974171 | 0.75 | PTPN7 (0.70) | PTPN7HMGCRRECQLTDP1KDM4E | |
| SCHEMBL26205611 | 0.73 | TSHR (0.37) | BLMKMT2A | |
| SCHEMBL11117824 | 0.72 | ACE2 (0.58) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL10919003 | 0.71 | RECQL (0.73) | PTPN7HMGCRRECQLTDP1KDM4E | |
| SCHEMBL10803234 | 0.71 | RECQL (0.73) | PTPN7HMGCRRECQLTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PTPN7 26/4885HMGCR 2301/4885RECQL 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.